IN8bio cuts staff and pipeline to focus on AML cell therapy
The company has reduced its headcount by about 49% and suspended enrolment in a Phase II glioblastoma trial.
The company has reduced its headcount by about 49% and suspended enrolment in a Phase II glioblastoma trial.